{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+once+daily&page=23",
    "query": {
      "intervention": "Placebo once daily",
      "page": 23
    },
    "page_size": 10
  },
  "pagination": {
    "page": 23,
    "page_size": 10,
    "total_count": 5497,
    "total_pages": 550,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+once+daily&page=24&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+once+daily&page=22&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-15T20:55:09.136Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01542788",
      "title": "Sofosbuvir + Ribavirin for 12 Weeks in Subjects With Chronic Genotype 2 or 3 Hepatitis C Infection Who Are Interferon Intolerant, Interferon Ineligible or Unwilling to Take Interferon",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Chronic Hepatitis C"
      ],
      "interventions": [
        {
          "name": "SOF",
          "type": "DRUG"
        },
        {
          "name": "RBV",
          "type": "DRUG"
        },
        {
          "name": "Placebo to match SOF",
          "type": "DRUG"
        },
        {
          "name": "Placebo to match RBV",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Gilead Sciences",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 278,
      "start_date": "2012-03",
      "completion_date": "2013-02",
      "has_results": true,
      "last_update_posted_date": "2014-05-19",
      "last_synced_at": "2026-10-15T20:55:09.136Z",
      "location_count": 50,
      "location_summary": "Birmingham, Alabama • Coronado, California • Los Angeles, California + 40 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Coronado",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01542788"
    },
    {
      "nct_id": "NCT02394769",
      "title": "ASPirin Intervention for the REDuction of Colorectal Cancer Risk",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Colorectal Cancer"
      ],
      "interventions": [
        {
          "name": "Aspirin",
          "type": "DRUG"
        },
        {
          "name": "Placebo for Aspirin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Massachusetts General Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 180,
      "start_date": "2015-07-06",
      "completion_date": "2029-07",
      "has_results": true,
      "last_update_posted_date": "2025-12-04",
      "last_synced_at": "2026-10-15T20:55:09.136Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02394769"
    },
    {
      "nct_id": "NCT01710722",
      "title": "The Effect of Leptin A-200, Caffeine/Ephedrine and Their Combination Upon Weight Loss and Body Composition in Man",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Obesity"
      ],
      "interventions": [
        {
          "name": "caffeine and ephedrine",
          "type": "DRUG"
        },
        {
          "name": "Leptin A",
          "type": "DRUG"
        },
        {
          "name": "caffeine, ephedrine, and leptin A",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pennington Biomedical Research Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "18 Years to 60 Years"
      },
      "enrollment_count": 45,
      "start_date": "2001-02",
      "completion_date": "2002-02",
      "has_results": false,
      "last_update_posted_date": "2015-12-18",
      "last_synced_at": "2026-10-15T20:55:09.136Z",
      "location_count": 1,
      "location_summary": "Baton Rouge, Louisiana",
      "locations": [
        {
          "city": "Baton Rouge",
          "state": "Louisiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01710722"
    },
    {
      "nct_id": "NCT01328951",
      "title": "A Study of First-line Maintenance Erlotinib Versus Erlotinib at Disease Progression in Participants With Advanced Non-Small Cell Lung Cancer (NSCLC) Who Have Not Progressed Following Platinum-Based Chemotherapy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Non-Squamous Non-Small Cell Lung Cancer"
      ],
      "interventions": [
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Erlotinib",
          "type": "DRUG"
        },
        {
          "name": "Second-Line Chemotherapy",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Hoffmann-La Roche",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 643,
      "start_date": "2011-09",
      "completion_date": "2016-01",
      "has_results": true,
      "last_update_posted_date": "2016-10-28",
      "last_synced_at": "2026-10-15T20:55:09.136Z",
      "location_count": 9,
      "location_summary": "Gilroy, California • Washington D.C., District of Columbia • Kansas City, Missouri + 6 more",
      "locations": [
        {
          "city": "Gilroy",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Kansas City",
          "state": "Missouri"
        },
        {
          "city": "Missoula",
          "state": "Montana"
        },
        {
          "city": "Lebanon",
          "state": "New Hampshire"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01328951"
    },
    {
      "nct_id": "NCT02253745",
      "title": "Safety, Tolerability, PK & Efficacy of V81444 in Volunteers With Attention Deficit/ Hyperactivity Disorder (ADHD)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "ADHD"
      ],
      "interventions": [
        {
          "name": "V81444",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Vernalis (R&D) Ltd",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 31,
      "start_date": "2013-07",
      "completion_date": "2014-04",
      "has_results": false,
      "last_update_posted_date": "2016-06-03",
      "last_synced_at": "2026-10-15T20:55:09.136Z",
      "location_count": 1,
      "location_summary": "Kansas City, Kansas",
      "locations": [
        {
          "city": "Kansas City",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02253745"
    },
    {
      "nct_id": "NCT00019747",
      "title": "Surgery With or Without Thalidomide in Treating Patients With Recurrent or Metastatic Colorectal Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Colorectal Cancer"
      ],
      "interventions": [
        {
          "name": "thalidomide",
          "type": "DRUG"
        },
        {
          "name": "adjuvant therapy",
          "type": "PROCEDURE"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE",
        "OTHER"
      ],
      "sponsor": "National Institutes of Health Clinical Center (CC)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 39,
      "start_date": "1999-08",
      "completion_date": "2008-12",
      "has_results": true,
      "last_update_posted_date": "2015-10-28",
      "last_synced_at": "2026-10-15T20:55:09.136Z",
      "location_count": 6,
      "location_summary": "Goshen, Indiana • Bethesda, Maryland • Winston-Salem, North Carolina + 2 more",
      "locations": [
        {
          "city": "Goshen",
          "state": "Indiana"
        },
        {
          "city": "Bethesda",
          "state": "Maryland"
        },
        {
          "city": "Bethesda",
          "state": "Maryland"
        },
        {
          "city": "Winston-Salem",
          "state": "North Carolina"
        },
        {
          "city": "Cincinnati",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00019747"
    },
    {
      "nct_id": "NCT07840326",
      "title": "A Phase 2a Study of SUN-627 in Participants With Non-Active Secondary Progressive and Primary Progressive Multiple Sclerosis (SPMS/PPMS)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Primary Progressive Multiple Sclerosis",
        "Primary Progressive MS",
        "Primary Progressive Multiple Sclerosis (PPMS)",
        "Secondary Progressive MS (SPMS)",
        "Secondary Progressive Multiple Sclerosis (SPMS)",
        "Secondary Progressive MS",
        "Non-Active SPMS",
        "Non-Active Secondary Progressive Multiple Sclerosis",
        "Secondary Progressive Multiple Sclerosis With Inflammatory Disease Activity"
      ],
      "interventions": [
        {
          "name": "SUN-627",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Sundance Biosciences, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 20,
      "start_date": "2026-10",
      "completion_date": "2027-07",
      "has_results": false,
      "last_update_posted_date": "2026-09-25",
      "last_synced_at": "2026-10-15T20:55:09.136Z",
      "location_count": 3,
      "location_summary": "Atlanta, Georgia • Raleigh, North Carolina • Columbus, Ohio",
      "locations": [
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Raleigh",
          "state": "North Carolina"
        },
        {
          "city": "Columbus",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07840326"
    },
    {
      "nct_id": "NCT00715117",
      "title": "The Efficacy of Low Dose Naltrexone Therapy in Children With Crohn's Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Crohn's Disease"
      ],
      "interventions": [
        {
          "name": "Naltrexone",
          "type": "DRUG"
        },
        {
          "name": "Placebo, sugar pill",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Milton S. Hershey Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Years",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "6 Years to 17 Years"
      },
      "enrollment_count": 14,
      "start_date": "2008-07",
      "completion_date": "2010-08",
      "has_results": true,
      "last_update_posted_date": "2018-09-06",
      "last_synced_at": "2026-10-15T20:55:09.136Z",
      "location_count": 1,
      "location_summary": "Hershey, Pennsylvania",
      "locations": [
        {
          "city": "Hershey",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00715117"
    },
    {
      "nct_id": "NCT00791973",
      "title": "Effect of Veramyst on the Nasal and Ocular Symptoms of the Early Reaction to Nasal Challenge With Allergen",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Allergic Rhinitis"
      ],
      "interventions": [
        {
          "name": "fluticasone furoate",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Chicago",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "ALL",
        "summary": "18 Years to 45 Years"
      },
      "enrollment_count": 15,
      "start_date": "2008-11",
      "completion_date": "2010-05",
      "has_results": true,
      "last_update_posted_date": "2014-07-08",
      "last_synced_at": "2026-10-15T20:55:09.136Z",
      "location_count": 1,
      "location_summary": "Chicago, Illinois",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00791973"
    },
    {
      "nct_id": "NCT02691494",
      "title": "Efficacy and Safety of Elagolix in Combination With Estradiol/Norethindrone Acetate for the Management of Heavy Menstrual Bleeding Associated With Uterine Fibroids in Premenopausal Women (Replicate Study)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Uterine Fibroids",
        "Heavy Menstrual Bleeding"
      ],
      "interventions": [
        {
          "name": "Elagolix",
          "type": "DRUG"
        },
        {
          "name": "Placebo for Estradiol/Norethindrone Acetate",
          "type": "DRUG"
        },
        {
          "name": "Estradiol/Norethindrone Acetate",
          "type": "DRUG"
        },
        {
          "name": "Placebo for Elagolix",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AbbVie",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "51 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 51 Years · Female only"
      },
      "enrollment_count": 378,
      "start_date": "2016-02-03",
      "completion_date": "2019-01-23",
      "has_results": true,
      "last_update_posted_date": "2021-07-13",
      "last_synced_at": "2026-10-15T20:55:09.136Z",
      "location_count": 103,
      "location_summary": "Birmingham, Alabama • Dothan, Alabama • Fairhope, Alabama + 89 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Dothan",
          "state": "Alabama"
        },
        {
          "city": "Fairhope",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Mesa",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02691494"
    }
  ]
}